A Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including...

Area of Science:

• Radiation Oncology
• Medical Physics
• Breast Cancer Treatment

Background:

• Hypofractionated radiotherapy is an evolving treatment modality for early-stage breast cancer.
• Assessing long-term cosmetic and well-being outcomes is crucial for patient-centered care.

Purpose of the Study:

• To evaluate the long-term physical appearance and well-being effects of hypofractionated radiotherapy with simultaneous integrated boost (SIB) in breast cancer patients.
• To compare outcomes associated with different radiotherapy techniques like IMRT, VMAT, or hybrid approaches.

Main Methods:

• Hypofractionated SIB-VMAT was administered to early-stage breast cancer patients over three weeks.
• Total doses: 48.06 Gy to the whole breast and 54 Gy to the tumor bed.
• Skin toxicity and cosmetic outcomes were assessed during acute, 3-month, and 5-year follow-up periods.

Main Results:

• Analysis included 125 patients with a minimum 5-year follow-up.
• Data collected between December 2014 and December 2016.
• Long-term data demonstrated acceptable toxicity and cosmetic results.

Conclusions:

• Hypofractionated SIB-VMAT is a safe and effective treatment for early-stage breast cancer.
• This technique offers a viable option for patients, including those with unfavorable prognostic factors.
• Positive long-term cosmetic and well-being outcomes support its continued use.